1832 Asset Management
GSK icon

1832 Asset Management’s GSK GSK Stock Holding History

1832 Asset Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,239
Closed -$125K – 763
2024
Q2 		$125K Buy
3,239
+161
+5% +$6.77K ﹤0.01% 663
2024
Q1 		$132K Buy
3,078
+257
+9% +$10.6K ﹤0.01% 654
2023
Q4 		$105K Hold
2,821
– – ﹤0.01% 653
2023
Q3 		$102K Hold
2,821
– – ﹤0.01% 665
2023
Q2 		$101K Sell
2,821
-42,471
-94% -$1.52M ﹤0.01% 672
2023
Q1 		$1.61M Sell
45,292
-6,464
-12% -$226K ﹤0.01% 534
2022
Q4 		$1.82M Sell
51,756
-14,679
-22% -$489K ﹤0.01% 549
2022
Q3 		$1.96M Buy
66,435
+1,511
+2% +$57.3K ﹤0.01% 512
2022
Q2 		$3.53M Buy
64,924
+62,024
+2,139% +$3.42M 0.01% 450
2022
Q1 		$156K Buy
2,900
+36
+1% +$1.96K ﹤0.01% 731
2021
Q4 		$157K Buy
2,864
+87
+3% +$4.53K ﹤0.01% 547
2021
Q3 		$136K Buy
2,777
+55
+2% +$2.76K ﹤0.01% 738
2021
Q2 		$135K Hold
2,722
– – ﹤0.01% 596
2021
Q1 		$121K Sell
2,722
-132,638
-98% -$6.02M ﹤0.01% 567
2020
Q4 		$6.29M Hold
135,360
– – 0.01% 334
2020
Q3 		$6.38M Sell
135,360
-12
-0% -$601 0.02% 303
2020
Q2 		$6.95M Buy
135,372
+12
+0% +$616 0.02% 267
2020
Q1 		$6.41M Hold
135,360
– – 0.02% 275
2019
Q4 		$8.01M Sell
135,360
-225
-0.2% -$12.5K 0.02% 250
2019
Q3 		$7.17M Buy
135,585
+155
+0.1% +$7.97K 0.02% 254
2019
Q2 		$6.77M Buy
135,430
+134,858
+23,577% +$6.77M 0.02% 264
2019
Q1 		$30K Sell
572
-202
-26% -$10.1K ﹤0.01% 530
2018
Q4 		$37K Buy
774
+202
+35% +$9.95K ﹤0.01% 502
2018
Q3 		$29K Sell
572
-82
-13% -$4.17K ﹤0.01% 565
2018
Q2 		$33K Buy
654
+82
+14% +$4.13K ﹤0.01% 529
2018
Q1 		$28K Sell
572
-9,120
-94% -$425K ﹤0.01% 560
2017
Q4 		$428K Sell
9,692
-11,040
-53% -$510K ﹤0.01% 472
2017
Q3 		$1.02M Buy
20,732
+3,200
+18% +$162K ﹤0.01% 423
2017
Q2 		$946K Buy
17,532
+16,960
+2,965% +$904K ﹤0.01% 448
2017
Q1 		$30K Sell
572
-288,711
-100% -$14.6M ﹤0.01% 615
2016
Q4 		$10.1M Buy
289,283
+256,231
+775% +$12.7M 0.02% 362
2016
Q3 		$1.78M Sell
33,052
-5,380
-14% -$295K 0.01% 399
2016
Q2 		$2.1M Sell
38,432
-3,280
-8% -$173K 0.01% 357
2016
Q1 		$3.54M Sell
41,712
-2,400
-5% -$120K 0.01% 355
2015
Q4 		$2.27M Buy
44,112
+4,340
+11% +$221K 0.01% 351
2015
Q3 		$1.92M Buy
39,772
+8,400
+27% +$437K 0.01% 358
2015
Q2 		$1.63M Buy
31,372
+30,788
+5,272% +$1.73M 0.01% 422
2015
Q1 		$34K Sell
584
-56
-9% -$3.21K ﹤0.01% 510
2014
Q4 		$34K Buy
640
+80
+14% +$4.48K ﹤0.01% 522
2014
Q3 		$32K Hold
560
– – ﹤0.01% 530
2014
Q2 		$37K Hold
560
– – ﹤0.01% 518
2014
Q1 		$37K Buy
+560
New +$37.9K ﹤0.01% 522

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

1832 Asset Management's GSK Position: Q3 2024 in Review

1832 Asset Management sold out of GSK (GSK) in Q3 2024, closing a stake of 3,239 shares — an estimated $125K sold.

1832 Asset Management first reported a position in GSK in Q1 2014 and held it in 42 quarters. The position peaked at $10.1M in Q4 2016. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

  • 1832 Asset Management reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
  • 1832 Asset Management sold 3,239 GSK shares in Q3 2024, an estimated $125K.
  • 1832 Asset Management first reported a position in GSK in Q1 2014 and held it in 42 quarters.
  • 1832 Asset Management's GSK position peaked at $10.1M in Q4 2016.
  • 899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on 1832 Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.